EPLAW PATENT BLOG

EU – General Court partially annuls EC’s decision on restrictive agreements and abuse of dominant positionon the market for perindopril

Posted: December 13th, 2018

Judgments in Cases T-677/14 Biogaran v. Commission, T-679/14 Teva UK and Others v. Commission, T680/14 Lupin v. Commission, T-682/14 Mylan Laboratories and Mylan v. Commission, T-684/14 Krka v. Commission, T-701/14 Niche Generics v. Commission, T-705/14 Unichem Laboratories v. Commission, T-691/14 Servier and Others v. Commission, General Court of the European Union, Luxembourg, 12 December 2018

PRESS RELEASE No 194/18:

The General Court annuls in part the European Commission’s decision finding the existence of restrictive agreements and an abuse of a dominant position on the market for perindopril, a medicine used to treat hypertension and heart failure.

The General Court confirms, however, that certain patent settlement agreements may be restrictive of competition by object

The full press release can be read here.

The full text of the judgments can be read here: T-677/14, T-679/14, T-680/14, T-682/14, T-684/14, T-701/14, T-705/14T-691/14.

Leave a Reply